Open Access

Influence of SLCO1B1 in gastric cancer patients treated with EOF chemotherapy

  • Authors:
    • Wanjing Feng
    • Xin Liu
    • Xiaoying Zhao
    • Mingzhu Huang
    • Weijian Guo
    • Jiliang Yin
    • Zhiyu Chen
    • Xiaodong Zhu
  • View Affiliations

  • Published online on: July 16, 2018     https://doi.org/10.3892/ol.2018.9147
  • Pages: 4489-4497
  • Copyright: © Feng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cytochrome‑P450 enzymes, ATP‑binding cassette transporters, and solute carriers mediate drug metabolism as metabolic enzymes and membrane transporters, respectively. The present study investigated whether single nucleotide polymorphisms (SNPs) in genes encoding these proteins were predictive or prognostic factors in patients with metastatic gastric cancer (MGC) undergoing chemotherapy. A retrospective study of 108 MGC patients who received epirubicin, oxaliplatin, and 5‑fluorouracil (EOF) as first‑line treatment was performed. A total of 13 SNPs were genotyped, including SLCO1B1 (rs4149056), SLC2A9 (rs16890979, rs6449213, rs734553), ABCG2 (rs2231142), CYP2C9 (rs1057910, rs1799853), CYP2C19 (rs72552267, rs28399504, rs56337013, rs41291556) and CYP1A2 (rs12720461, rs56107638). The associations between these genotypes and disease‑control rate (DCR), progression‑free survival (PFS) and overall survival (OS) were analyzed. Patients with SLCO1B1 rs4149056 TT genotype had a significantly shorter OS compared with those with a C allele (CC + CT; 312 vs. 565 days, P=0.039). Multivariate analysis revealed that the rs4149056 TT homozygous genotype was an independent prognostic factor for shorter OS (hazard ratio: 2.565, 95% confidence interval: 1.215‑5.415, P=0.014). However, no significant associations between SLCO1B1 rs4149056 and PFS were observed, between the other 12 SNPs and PFS or OS, or between any of the 13 SNPs and DCR. In conclusion, SLCO1B1 rs4149056 TT may be an independent predictor of survival in patients with MCG treated with EOF chemotherapy.
View Figures
View References

Related Articles

Journal Cover

October-2018
Volume 16 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Feng W, Liu X, Zhao X, Huang M, Guo W, Yin J, Chen Z and Zhu X: Influence of SLCO1B1 in gastric cancer patients treated with EOF chemotherapy. Oncol Lett 16: 4489-4497, 2018
APA
Feng, W., Liu, X., Zhao, X., Huang, M., Guo, W., Yin, J. ... Zhu, X. (2018). Influence of SLCO1B1 in gastric cancer patients treated with EOF chemotherapy. Oncology Letters, 16, 4489-4497. https://doi.org/10.3892/ol.2018.9147
MLA
Feng, W., Liu, X., Zhao, X., Huang, M., Guo, W., Yin, J., Chen, Z., Zhu, X."Influence of SLCO1B1 in gastric cancer patients treated with EOF chemotherapy". Oncology Letters 16.4 (2018): 4489-4497.
Chicago
Feng, W., Liu, X., Zhao, X., Huang, M., Guo, W., Yin, J., Chen, Z., Zhu, X."Influence of SLCO1B1 in gastric cancer patients treated with EOF chemotherapy". Oncology Letters 16, no. 4 (2018): 4489-4497. https://doi.org/10.3892/ol.2018.9147